Quarterly report pursuant to Section 13 or 15(d)

REVENUES

v3.24.1.1.u2
REVENUES
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUES

NOTE 9 – REVENUES

 

Disaggregation of Net Revenues

 

The Company’s net product revenues are summarized below:

 

                 
   

Three months ended

March 31,

  
    2024   2023  
Zembrace Symtouch   $ 1,847   $ —  
Tosymra     635     —  
Total product revenues   $ 2,482   $ —  

 

All sales are generated in the United States.

 

Gross-to-Net Sales Accruals

 

We record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary to the pharmaceutical industry.

 

Our provision for gross-to-net allowances was $3.0 million at March 31, 2024, $0.6 million of which was recorded as a reduction to accounts receivable and $2.4 million recorded as a component of accrued expenses.